ibi343
mAbexperimentalADC
Clinical trial activity
6 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
5
Phase 3
2
Phase 4
0
Earliest trial started Oct 26, 2022 (NCT05458219)
Timeline
Indications
Mechanism of action
- Claudin-18Immunity, passive
CLDN18 immunity, passive
Chemistry & pharmacology
- Payload
- unclear
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07066098 | Phase 3 | Aug 4, 2025 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT07025889 | Phase 1/Phase 2 (Phase 2) | Jun 2, 2025 | Jiao Tong University |
| NCT06770439 | Phase 2 | Apr 18, 2025 | Zhejiang University |
| NCT06238843 | Phase 3 | Jun 30, 2024 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT06321913 | Phase 2 | Mar 15, 2024 | Harbin Medical University, Innovent Biologics (Suzhou) Co. Ltd. |
| NCT05458219 | Phase 1 | Oct 26, 2022 | Innovent Biologics (Suzhou) Co. Ltd. |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Innovent Biologics (Suzhou) Co. Ltd. | For profit | 4 | 3 | 3 | 2022 |
| Harbin Medical University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Jiao Tong University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Zhejiang University | Academic/Hospital | 1 | 1 | 1 | 2025 |
4 organizations
Page 1 / 1